Css LLC Il Acquires New Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

CSS LLC IL bought a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 610 shares of the biopharmaceutical company's stock, valued at approximately $435,000.

Several other institutional investors and hedge funds have also made changes to their positions in REGN. Merit Financial Group LLC raised its stake in Regeneron Pharmaceuticals by 8.9% during the 4th quarter. Merit Financial Group LLC now owns 868 shares of the biopharmaceutical company's stock valued at $618,000 after acquiring an additional 71 shares during the last quarter. Diversify Advisory Services LLC purchased a new stake in Regeneron Pharmaceuticals during the 4th quarter valued at approximately $234,000. Crossmark Global Holdings Inc. raised its stake in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Crossmark Global Holdings Inc. now owns 2,654 shares of the biopharmaceutical company's stock valued at $1,890,000 after acquiring an additional 92 shares during the last quarter. Atomi Financial Group Inc. raised its stake in Regeneron Pharmaceuticals by 7.0% during the 4th quarter. Atomi Financial Group Inc. now owns 615 shares of the biopharmaceutical company's stock valued at $438,000 after acquiring an additional 40 shares during the last quarter. Finally, Dakota Wealth Management raised its stake in shares of Regeneron Pharmaceuticals by 2.9% during the 4th quarter. Dakota Wealth Management now owns 1,366 shares of the biopharmaceutical company's stock worth $973,000 after buying an additional 39 shares in the last quarter. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Trading Up 2.5%

Shares of NASDAQ REGN traded up $14.79 during midday trading on Tuesday, hitting $603.13. The stock had a trading volume of 574,820 shares, compared to its average volume of 801,640. The company has a market capitalization of $65.12 billion, a price-to-earnings ratio of 15.76, a PEG ratio of 2.34 and a beta of 0.43. Regeneron Pharmaceuticals, Inc. has a 1-year low of $520.50 and a 1-year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09. The company has a fifty day moving average price of $590.70 and a 200 day moving average price of $672.23.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a return on equity of 16.32% and a net margin of 31.07%. The business had revenue of $3.03 billion for the quarter, compared to analysts' expectations of $3.40 billion. During the same quarter in the prior year, the firm earned $9.55 earnings per share. Regeneron Pharmaceuticals's revenue for the quarter was down 3.7% compared to the same quarter last year. On average, analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, June 6th. Stockholders of record on Tuesday, May 20th will be issued a $0.88 dividend. The ex-dividend date of this dividend is Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.58%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is 8.96%.

Wall Street Analysts Forecast Growth

Several brokerages have commented on REGN. Royal Bank of Canada restated an "outperform" rating and set a $943.00 target price on shares of Regeneron Pharmaceuticals in a research report on Tuesday. Leerink Partners upgraded shares of Regeneron Pharmaceuticals from a "market perform" rating to an "outperform" rating and boosted their target price for the stock from $762.00 to $834.00 in a research report on Wednesday, February 5th. Guggenheim lowered their price target on Regeneron Pharmaceuticals from $940.00 to $810.00 and set a "buy" rating on the stock in a report on Thursday, May 1st. Wall Street Zen cut Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. Finally, Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. One analyst has rated the stock with a sell rating, four have issued a hold rating, nineteen have given a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $890.60.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.